GlassScriptPhysician profile
Sunket Ahkee
NPI 1023111580
$7,811.25
in general payments reported to CMS, 2019-2025
21 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $507 · 2021: $504 · 2022: $2,070 · 2023: $852 · 2024: $1,525 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,768 · Education: $21.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.39 |
| Education | $21.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,798.74 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $891.32 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Gilead Sciences, INC. | $833.89 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $725.60 | 2019-2022 | |
| Cipla USA INC. | $720.20 | 2022 | |
| Insmed, INC. | $621.75 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $587.67 | 2020-2025 | Teflaro, Dalvance |
| Janssen Products, LP | $395.16 | 2019-2022 | |
| Melinta Therapeutics, LLC | $317.81 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Shionogi INC | $315.27 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $183.37 | 2020-2024 | Nuzyra |
| Theratechnologies INC. | $137.29 | 2019-2025 | Egrifta, Trogarzo |
| Ferring Pharmaceuticals INC. | $68.34 | 2025 | Rebyota |
| Angiodynamics, INC. | $44.43 | 2019 | |
| Emd Serono, INC. | $37.62 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $28.83 | 2020-2024 | Vibativ |
| Mylan Institutional INC. | $24.49 | 2019 | |
| La Jolla Pharmaceutical Company | $24.33 | 2023 | Xerava |
| Vyera Pharmaceuticals, LLC | $22.26 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $17.19 | 2019 | |
| Allergan, INC. | $15.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunket Ahkee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.